| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 3.0 | 10.8 |
| Net income | -20.3 | -9.2 |
| EPS (diluted, $ a share) | $-0.93 | $-0.72 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -72.6% |
|---|
10-Q filed with the SEC, NASDAQ: ASMB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Assembly Biosciences, Inc.: key numbers
- Share price
- $21.29Close, Nov 16
- Market cap
- $436M
- Shares outstanding
- 20.48MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Assembly Biosciences, Inc.
All →Assembly Biosciences Financial Results
Assembly Biosciences reported Q3 2026 financial results and announced the receipt of a $75 million collaboration extension fee from Gilead Sciences, extending its cash runway into 2029. The company also exercised its option to share 40% of U.S. development costs and profits for the HSV helicase primase inhibitor program and initiated a Phase 2 study for ABI-6250 in chronic hepatitis delta virus.
- Counterparty
- Gilead Sciences, Inc.
“This quarter, we rapidly advanced our liver disease program by initiating the Phase 2 study of ABI-6250 in chronic hepatitis delta virus and preparing for our Phase 2 study in cholestatic liver diseases, which we expect to begin in the first quarter next year. Alongside that progress, we elected to share U.S. costs and profits for the HSV helicase primase inhibitor program under our collaboration with Gilead, a decision we believe represents a significant opportunity to build long-term value. With a strong financial position, we look forward to the continued expansion of our pipeline and advancement of the herpesvirus and liver disease programs through their respective Phase 2 studies.”
Jason Okazaki, chief executive officer and president of Assembly Bio
Assembly Biosciences PFO and PAO Jeanette M. Bjorkquist Sells $14.1K of Stock
Jeanette M. Bjorkquist, PFO and PAO, sold 718 shares of Assembly Biosciences, Inc. at $19.61 a share, worth $14.1K in total on Nov 2, 2026. Shares held after the trade: 17,682 (-3.9%).
- Value
- $14.1K
- Shares
- 718
- Price
- $19.61
- Role
- PFO and PAO
- Holding change
- -3.9%
- Trade date
- Nov 2, 2026
Assembly Biosciences Chief Manufacturing Officer Nicole S. White Sells $50.3K of Stock
Nicole S. White, Chief Manufacturing Officer, sold 2,564 shares of Assembly Biosciences, Inc. at $19.61 a share, worth $50.3K in total on Nov 2, 2026. Shares held after the trade: 59,286 (-4.1%).
- Value
- $50.3K
- Shares
- 2,564
- Price
- $19.61
- Role
- Chief Manufacturing Officer
- Holding change
- -4.1%
- Trade date
- Nov 2, 2026
Assembly Biosciences CMO Anuj Gaggar Sells $50.3K of Stock
Anuj Gaggar, CMO, sold 2,564 shares of Assembly Biosciences, Inc. at $19.61 a share, worth $50.3K in total on Nov 2, 2026. Shares held after the trade: 53,829 (-4.5%).
- Value
- $50.3K
- Shares
- 2,564
- Price
- $19.61
- Role
- CMO
- Holding change
- -4.5%
- Trade date
- Nov 2, 2026
Assembly Biosciences CEO and President Jason A. Okazaki Sells $120K of Stock
Jason A. Okazaki, CEO and President, sold 6,133 shares of Assembly Biosciences, Inc. at $19.61 a share, worth $120K in total on Nov 2, 2026. Shares held after the trade: 195,601 (-3.0%).
- Value
- $120K
- Shares
- 6,133
- Price
- $19.61
- Role
- CEO and President
- Holding change
- -3.0%
- Trade date
- Nov 2, 2026